Cannabinoid receptor localization in brain.
PDF (1.6M)
+2 authors
Journal: 1990/April - Proceedings of the National Academy of Sciences of the United States of America
ISSN: 0027-8424
PUBMED: 2308954
Abstract:
[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than delta 9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections. The potencies of a series of natural and synthetic cannabinoids as competitors of [3H]CP 55,940 binding correlated closely with their relative potencies in several biological assays, suggesting that the receptor characterized in our in vitro assay is the same receptor that mediates behavioral and pharmacological effects of cannabinoids, including human subjective experience. Autoradiography of cannabinoid receptors in brain sections from several mammalian species, including human, reveals a unique and conserved distribution; binding is most dense in outflow nuclei of the basal ganglia--the substantia nigra pars reticulata and globus pallidus--and in the hippocampus and cerebellum. Generally high densities in forebrain and cerebellum implicate roles for cannabinoids in cognition and movement. Sparse densities in lower brainstem areas controlling cardiovascular and respiratory functions may explain why high doses of delta 9-tetrahydrocannabinol are not lethal.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(429)
References
(39)
Clinical trials
(1)
Chemicals
(5)
Organisms
(3)
Processes
(3)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Proc Natl Acad Sci U S A 87(5): 1932-1936
PMID: 2308954

Cannabinoid receptor localization in brain.

Abstract

[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than delta 9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections. The potencies of a series of natural and synthetic cannabinoids as competitors of [3H]CP 55,940 binding correlated closely with their relative potencies in several biological assays, suggesting that the receptor characterized in our in vitro assay is the same receptor that mediates behavioral and pharmacological effects of cannabinoids, including human subjective experience. Autoradiography of cannabinoid receptors in brain sections from several mammalian species, including human, reveals a unique and conserved distribution; binding is most dense in outflow nuclei of the basal ganglia--the substantia nigra pars reticulata and globus pallidus--and in the hippocampus and cerebellum. Generally high densities in forebrain and cerebellum implicate roles for cannabinoids in cognition and movement. Sparse densities in lower brainstem areas controlling cardiovascular and respiratory functions may explain why high doses of delta 9-tetrahydrocannabinol are not lethal.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 1932
1932
icon of scanned page 1933
1933
icon of scanned page 1934
1934
icon of scanned page 1935
1935
icon of scanned page 1936
1936

Images in this article

Image
Image
on p.1934
Image
Image
on p.1935
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev. 1986 Jun;38(2):75–149. [PubMed] [Google Scholar]
  • Dewey WL. Cannabinoid pharmacology. Pharmacol Rev. 1986 Jun;38(2):151–178. [PubMed] [Google Scholar]
  • Hollister LE. Health aspects of cannabis. Pharmacol Rev. 1986 Mar;38(1):1–20. [PubMed] [Google Scholar]
  • Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J Med Chem. 1975 Jul;18(7):700–703. [PubMed] [Google Scholar]
  • Wilson RS, May EL. 9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, Some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols. J Med Chem. 1976 Sep;19(9):1165–1167. [PubMed] [Google Scholar]
  • Wilson RS, May EL, Dewey WL. Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties. J Med Chem. 1979 Jul;22(7):886–888. [PubMed] [Google Scholar]
  • Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988 Nov;34(5):605–613. [PubMed] [Google Scholar]
  • Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol. 1988 Mar;33(3):297–302. [PubMed] [Google Scholar]
  • Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988 Dec;247(3):1046–1051. [PubMed] [Google Scholar]
  • Rothman RB, Schumacher UK, Pert CB. Binding of radiolabeled opiates to slide-mounted sections of molded minced rat brain: a novel method for conducting radioreceptor assays. Neuropeptides. 1983 Oct;3(6):493–499. [PubMed] [Google Scholar]
  • Rothman RB. Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies. Alcohol Drug Res. 1985;6(5):309–325. [PubMed] [Google Scholar]
  • McGonigle P, Neve KA, Molinoff PB. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Mol Pharmacol. 1986 Oct;30(4):329–337. [PubMed] [Google Scholar]
  • Rothman RB, Long JB, Bykov V, Jacobson AE, Rice KC, Holaday JW. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. J Pharmacol Exp Ther. 1988 Nov;247(2):405–416. [PubMed] [Google Scholar]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  • Burstein SH, Hull K, Hunter SA, Latham V. Cannabinoids and pain responses: a possible role for prostaglandins. FASEB J. 1988 Nov;2(14):3022–3026. [PubMed] [Google Scholar]
  • Nye JS, Seltzman HH, Pitt CG, Snyder SH. High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol. J Pharmacol Exp Ther. 1985 Sep;234(3):784–791. [PubMed] [Google Scholar]
  • Zezula J, Cortés R, Probst A, Palacios JM. Benzodiazepine receptor sites in the human brain: autoradiographic mapping. Neuroscience. 1988 Jun;25(3):771–795. [PubMed] [Google Scholar]
  • Boyson SJ, McGonigle P, Molinoff PB. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci. 1986 Nov;6(11):3177–3188.[PMC free article] [PubMed] [Google Scholar]
  • Richfield EK, Young AB, Penney JB. Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res. 1986 Sep 24;383(1-2):121–128. [PubMed] [Google Scholar]
  • Greenamyre JT, Young AB, Penney JB. Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. J Neurosci. 1984 Aug;4(8):2133–2144.[PMC free article] [PubMed] [Google Scholar]
  • Garrett ER, Hunt CA. Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. J Pharm Sci. 1974 Jul;63(7):1056–1064. [PubMed] [Google Scholar]
  • Harris LS, Carchman RA, Martin BR. Evidence for the existence of specific cannabinoid binding sites. Life Sci. 1978 Apr 3;22(13-15):1131–1137. [PubMed] [Google Scholar]
  • Roth SH, Williams PJ. The non-specific membrane binding properties of delta9-tetrahydrocannabinol and the effects of various solubilizers. J Pharm Pharmacol. 1979 Apr;31(4):224–230. [PubMed] [Google Scholar]
  • Worley PF, Baraban JM, De Souza EB, Snyder SH. Mapping second messenger systems in the brain: differential localizations of adenylate cyclase and protein kinase C. Proc Natl Acad Sci U S A. 1986 Jun;83(11):4053–4057.[PMC free article] [PubMed] [Google Scholar]
  • Worley PF, Baraban JM, Snyder SH. Heterogeneous localization of protein kinase C in rat brain: autoradiographic analysis of phorbol ester receptor binding. J Neurosci. 1986 Jan;6(1):199–207.[PMC free article] [PubMed] [Google Scholar]
  • Miller LL, Branconnier RJ. Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull. 1983 May;93(3):441–456. [PubMed] [Google Scholar]
  • Aigner TG. Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys. Psychopharmacology (Berl) 1988;95(4):507–511. [PubMed] [Google Scholar]
  • Douglas RJ. The hippocampus and behavior. Psychol Bull. 1967 Jun;67(6):416–422. [PubMed] [Google Scholar]
  • Eichenbaum H, Cohen NJ. Representation in the hippocampus: what do hippocampal neurons code? Trends Neurosci. 1988 Jun;11(6):244–248. [PubMed] [Google Scholar]
  • Hooker WD, Jones RT. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology (Berl) 1987;91(1):20–24. [PubMed] [Google Scholar]
  • Schulze GE, McMillan DE, Bailey JR, Scallet A, Ali SF, Slikker W, Jr, Paule MG. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests. J Pharmacol Exp Ther. 1988 Apr;245(1):178–186. [PubMed] [Google Scholar]
  • Campbell KA, Foster TC, Hampson RE, Deadwyler SA. Effects of delta 9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. J Pharmacol Exp Ther. 1986 Dec;239(3):941–945. [PubMed] [Google Scholar]
  • Kornetsky C. Brain-stimulation reward: a model for the neuronal bases for drug-induced euphoria. NIDA Res Monogr. 1985;62:30–50. [PubMed] [Google Scholar]
  • Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274–5278.[PMC free article] [PubMed] [Google Scholar]
  • Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, Gardner EL. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res. 1988 Jun 7;451(1-2):59–68. [PubMed] [Google Scholar]
  • Stark P, Dews PB. Cannabinoids. I. Behavioral effects. J Pharmacol Exp Ther. 1980 Jul;214(1):124–130. [PubMed] [Google Scholar]
  • Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, Morrison D. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology (Berl) 1988;96(1):142–144. [PubMed] [Google Scholar]
  • Petro DJ, Ellenberger C., Jr Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol. 1981 Aug-Sep;21(8-9):413S–416S. [PubMed] [Google Scholar]
  • Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol. 1983 Jun;13(6):669–671. [PubMed] [Google Scholar]
Unit on Functional Neuroanatomy, National Institute of Mental Health, Bethesda, MD 20892.
Unit on Functional Neuroanatomy, National Institute of Mental Health, Bethesda, MD 20892.
Copyright notice
Abstract
[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than delta 9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections. The potencies of a series of natural and synthetic cannabinoids as competitors of [3H]CP 55,940 binding correlated closely with their relative potencies in several biological assays, suggesting that the receptor characterized in our in vitro assay is the same receptor that mediates behavioral and pharmacological effects of cannabinoids, including human subjective experience. Autoradiography of cannabinoid receptors in brain sections from several mammalian species, including human, reveals a unique and conserved distribution; binding is most dense in outflow nuclei of the basal ganglia--the substantia nigra pars reticulata and globus pallidus--and in the hippocampus and cerebellum. Generally high densities in forebrain and cerebellum implicate roles for cannabinoids in cognition and movement. Sparse densities in lower brainstem areas controlling cardiovascular and respiratory functions may explain why high doses of delta 9-tetrahydrocannabinol are not lethal.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.